Hyderabad: Doctors caution using beta blockers without supervision of a physician

Hyderabad: A recent study conducted by faculty members at St. George's University School of Medicine sheds light on the efficacy and safety of beta blockers in managing heart health on a global scale.

Dr. Rohit Mishra and Dr. Aishwarya Singh, both Assistant Professors of Pathology at St. George's University have spearheaded research aimed at evaluating the benefits and risks associated with beta-blockers, a class of medications commonly used to manage abnormal heart rhythms and prevent heart attacks from recurring.

Understanding Beta Blockers

Beta-blockers have long been a cornerstone in the treatment of cardiovascular diseases, including hypertension, heart failure, and ischemic heart disease. These medications work by blocking the effects of adrenaline, thereby reducing heart rate and blood pressure, ultimately easing the workload on the heart.

Research Findings

The findings of the study, published in their book "Beta Blocker: Its Effect and Safety," offer promising insights into the role of beta blockers in improving heart health outcomes.

According to Dr. Mishra, the research demonstrates the safety and effectiveness of beta-blockers, particularly in patients with hypertension, diabetes, anxiety, and other co-existing conditions.

“However, it's crucial to note that the effectiveness of beta-blockers may vary among individuals based on factors such as medical history and gender,” said Dr. Mishra.

Dr. Mishra emphasizes the importance of physician supervision when using beta blockers, stating, "Patients should never use beta blockers without the supervision of a physician."

Dr. Singh echoes this sentiment, highlighting the significance of bridging the gap between research findings and clinical practice to address the pressing issue of cardiovascular diseases, a leading cause of death globally.

Implications for Global Health

The research findings hold significant implications for global heart health, especially in regions like the Middle East and North Africa (MENA) where cardiovascular diseases remain a significant burden.

By elucidating the efficacy of different beta-blockers in treating heart diseases across diverse populations, the study aims to empower both patients and healthcare professionals with valuable insights into optimizing treatment strategies.